GNFTF News and Press, Genfit

Coverage and future reimbursement ( effective August 10, 2026) secured for NASHnext®, Labcorp’s non-invasive blood-based diagnostic test powered by GENFIT’s proprietary NIS4® technology Focuses on patients at highest risk, including those with prediabetes, type 2 diabe...

Investigational drug GNS561 showed a favorable safety and tolerability profile in a Phase 1b study evaluating its potential in combination with a MEK inhibitor (MEKi) Study conducted in a heavily pretreated, high - unmet - need population of KRAS - mutated cholangiocarcinoma (CCA) patients who...

All resolutions recommended by the Board of Directors approved (quorum: 32.13 %) Lille (France); Cambridge, ( Massachusetts, United States); Zurich (Switzerland); June 15, 2026 - GENFIT (Euronext: GNFT) , , a biopharmaceutical company dedicated to improving the lives of patients with r...

Labcorp OnDemand enables convenient testing with the NASHnext® test, within a physician-directed care pathway to support identification of patients with at-risk MASH This model expands access and supports adoption of NASHnext®, enabling testing across a wider patient population ...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 25, 2026 – GENFIT (Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today highlights its broad participation at EASL ...

Cash and cash equivalents totaled €136.1 million as of March 31, 2026 €9.6 million in revenue for the first three months of 2026, from royalties on Ipsen’s sales of Iqirvo® (elafibranor) Positive momentum across all growth platforms, combining increased revenue v...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 11, 2026 - GENFIT (Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the May 11, 2026 Fr...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 20, 2026 - GENFIT (Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces the publication of its 2026 extra-fi...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 07, 2026 - GENFIT (Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces the filing of its 2025 Universal Regis...

2025 financial highlights: Cash and cash equivalents totaled €101.1 million as of December 31, 2025 Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and €21.8 in royalties from Ipsen Cash runway...